Journal: The Lancet Regional Health: Western Pacific

Article Title: Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial

doi: 10.1016/j.lanwpc.2023.100829

Figure Lengend Snippet: Serum neutralising activities against SARS-CoV2 wild-type and variants of concern (beta, delta and omicron) before and after boosting, measured by ACE2-binding assay. Neutralising capacity measured by ACE2-binding assay in serum of participants who had received heterologous Convidecia and homologous CoronaVac immunisation at day 0 (a) and day 14 (b). Inhibition of ACE2 binding was measured against the wide-type, beta, delta, and omicron Spike proteins. Horizontal bars show the median, and error bars indicate interquartile range (IQR). Group A, primed with two doses of CoronaVac and given one dose of Convidecia (n = 50); Group B, primed with two doses of CoronaVac and given one dose of CoronaVac (n = 50); ACE2, angiotensin-converting enzyme 2.

Article Snippet: Additionally, we used the Spike- ACE2 binding inhibition assay (Meso Scale Discovery (MSD) platform) to test the functional neuralization capacity in samples from the first 100 participants in the three-dose regimen (50 each from the homologous and heterologous boost cohorts) as a post-hoc measurement for cross-reaction of beta (B.1.351), delta (B.1.617.2), and omicron subvariants (BA.2, BA.3, BA.4 and BA.5).

Techniques: Binding Assay, Inhibition

Journal: Pharmaceuticals

Article Title: Discovery of Natural Lead Compound from Dendrobium sp. against SARS-CoV-2 Infection

doi: 10.3390/ph15050620

Figure Lengend Snippet: The spike RBD and ACE2 binding inhibition of DB36 in a dose-dependent manner. Data are expressed as the relative mean value with an error bar (SEM) from three independent experiments (each performed in duplicate). BS-R2B2 (MonoRab SARS-CoV-2 neutralizing antibody) at 1 µg/mL was used as a positive control. The letter ‘a’ denotes a significant difference compared with the negative control ( p < 0.05) based on one-way ANOVA using GraphPad Prism 5.02.

Article Snippet: The COVID-19 Spike-ACE2 Binding Assay Kit Controls (RayBiotech), which are the purified antibodies that do not inhibit or inhibit SARS-CoV-2 S–ACE2 binding, were used as negative and positive controls, respectively.

Techniques: Binding Assay, Inhibition, Positive Control, Negative Control

Journal: Pharmaceuticals

Article Title: Discovery of Natural Lead Compound from Dendrobium sp. against SARS-CoV-2 Infection

doi: 10.3390/ph15050620

Figure Lengend Snippet: Binding mode of DB36 (green color stick) located in the binding motif (RBM) region (orange color surface) at the interface area of the spike protein interacting with ACE2 receptor (cyan helix color): ( A ) Binding location of DB36 at RBD of apo conformation of spike protein comparing with other hits; ( B ) The superimposition of the docked pose of DB36 with the ACE2 bound conformation of the spike protein (PDB code: 7KMB, pink color); The red arrow showed the flexible loop three (residues 472–490) of the spike protein in conformations of ( A ) apo (orange color) and ( B ) ACE2 bound (pink color); ( C , D ) The interactions of DB36 with the residues at the interface area of the spike protein interacting with the ACE2 receptor.

Article Snippet: The COVID-19 Spike-ACE2 Binding Assay Kit Controls (RayBiotech), which are the purified antibodies that do not inhibit or inhibit SARS-CoV-2 S–ACE2 binding, were used as negative and positive controls, respectively.

Techniques: Binding Assay